RMC No. 17-2024 updates VAT-exempt medicines for key diseases, including inclusions and a hypertension medicine deletion tied to FDA publication.

Pharmaceutical companies, drugstores, hospitals, clinics, and VAT-registered sellers of medicines must immediately verify whether the medicines they sell are affected by the latest FDA-endorsed updates to the VAT-exempt medicines list. RMC No. 17-2024 publishes the full text of the November 29, 2023 letter from the Food and Drug Administration endorsing changes to the list of VAT-exempt products under Republic Act No. 10963, or the TRAIN Law, and Republic Act No. 11534, or the CREATE Act. The practical consequence is direct: certain medicines for cancer, diabetes, hypertension, kidney disease, mental illness, and tuberculosis may now be treated as VAT-exempt once covered by the FDA-published updates, while one hypertension medicine has been deleted from the VAT-exempt list.

What RMC No. 17-2024 Changes

RMC No. 17-2024 publishes an FDA endorsement updating the list of VAT-exempt medicines under the TRAIN Law and the CREATE Act. The update covers two types of changes. First, it includes certain medicines for cancer, diabetes, hypertension, kidney disease, mental illness, and tuberculosis in the list of VAT-exempt medicines. Second, it deletes a medicine for hypertension from that list.

This matters because VAT treatment affects pricing, invoicing, accounting entries, tax returns, and input-output VAT reconciliation. For businesses selling covered medicines, the question is no longer merely whether a product is used for a qualifying disease category. The controlling compliance question is whether the medicine is part of the FDA-published updated list endorsed for VAT exemption. Sellers should not apply VAT exemption based on general disease categories alone.

The issuance is also important for tax practitioners and corporate accountants searching for BIR VAT-exempt medicines Philippines, RMC 17-2024 VAT exemption, FDA list of VAT-exempt medicines, CREATE Act VAT-exempt medicines, and TRAIN Law VAT-exempt drugs. These are the operational search terms because the update affects product classification, point-of-sale tax coding, and billing treatment.

Who Is Most Affected

The most affected taxpayers are businesses in the pharmaceutical and healthcare supply chain. This includes drugstores, hospital pharmacies, distributors, importers, wholesalers, clinics, healthcare providers, and corporate taxpayers that sell or bill medicines to patients, employees, members, or institutional clients.

VAT-registered businesses are especially affected because they must correctly determine whether VAT should be imposed on sales invoices or official receipts covering medicines. A covered medicine that becomes VAT-exempt should not be treated in the same manner as ordinary VATable goods. Conversely, a hypertension medicine deleted from the VAT-exempt list should not continue to be treated as exempt merely because it was previously listed or because it falls within a disease category that may otherwise contain exempt medicines.

CFOs, tax managers, and accounting teams should also treat this issuance as a product-master-data issue. The VAT status of medicines should be mapped at the SKU or product level, not simply at the broad category level. For example, not every hypertension medicine is automatically exempt, and the issuance specifically notes both the inclusion of certain medicines for hypertension and the deletion of a medicine for hypertension.

Key Compliance Requirement and Effective Date

The key compliance requirement is to align VAT treatment with the FDA-published updates to the VAT-exempt medicines list. RMC No. 17-2024 expressly refers to Q&A No. 1 of RMC No. 99-2021 and reiterates that the VAT exemption of covered medicines and medical devices under the CREATE Act shall be effective on the date of publication by the FDA of the updates to the said list.

The issuance itself is dated January 26, 2024. However, the operative rule stated in the circular is not a separate fixed deadline counted from January 26, 2024. The effectiveness of the VAT exemption for covered medicines and medical devices is tied to the date when the FDA publishes the relevant updates to the list.

This distinction is critical. A business should not rely only on the date of the BIR circular when determining the VAT treatment of a specific medicine. It must verify the FDA publication of the updated VAT-exempt list and determine whether the particular medicine is included or deleted. The documentation trail should show when the product became covered by the published list and when the accounting system was updated.

Products and Disease Categories Covered

RMC No. 17-2024 identifies the following affected categories: cancer, diabetes, hypertension, kidney disease, mental illness, and tuberculosis. The update includes certain medicines under these categories and deletes a medicine for hypertension.

The circular does not state in its main text that all medicines for these diseases are exempt. It refers to an updated list. For business compliance, this means the product name, dosage form, and exact listing should be checked against the FDA-published update before treating the sale as VAT-exempt. A generic internal classification such as cancer medicine, diabetes medicine, or hypertension medicine is not sufficient by itself if the product is not in the applicable VAT-exempt list.

This is particularly important for drugstores and distributors with large inventories. A single product database may contain thousands of entries. If the VAT field is manually maintained, the accounting or tax team should ensure that only the affected medicines are updated. If the VAT field is pushed through an ERP, POS, or pharmacy management system, the change should be validated through sample invoices and sales reports.

Penalties and Tax Risks for Non-Compliance

RMC No. 17-2024 does not create a separate penalty provision. It does not state a new surcharge, interest rate, compromise penalty, or administrative fine specific to this update. The risk, however, is practical and significant: an incorrect VAT classification can cause wrong invoicing, wrong VAT returns, incorrect price treatment, customer disputes, and possible exposure during BIR audit.

If a VAT-exempt medicine is wrongly treated as VATable, customers may be overcharged VAT and the seller may need to address refund, credit, or accounting correction issues. If a non-exempt or deleted medicine is wrongly treated as VAT-exempt, the seller may face deficiency VAT exposure depending on the facts, records, and applicable tax rules. The circular does not quantify those consequences, so businesses should avoid assuming a specific penalty amount from this issuance alone.

What Businesses Should Do Now

First, obtain and review the FDA-published update to the VAT-exempt medicines list referenced in the November 29, 2023 FDA letter. The review should be done at the product level, not merely at the therapeutic category level.

Second, update the tax coding of affected medicines in the company inventory, ERP, POS, billing, pharmacy, and invoicing systems. Medicines newly included in the FDA-published list should be treated according to the VAT exemption from the proper effective date. The hypertension medicine deleted from the list should also be identified and reclassified as needed.

Third, preserve proof of the FDA publication date and the internal date of system implementation. This is important because the CREATE Act VAT exemption is effective on the date of FDA publication of the updates, as clarified in RMC No. 99-2021 and reiterated in RMC No. 17-2024.

Fourth, train front-line billing, pharmacy, sales, and accounting personnel. Many VAT mistakes happen not because the tax team is unaware of the rule, but because the product database, cashier system, and invoice templates are not aligned with the tax treatment.

Finally, conduct a short VAT classification audit for medicines falling under cancer, diabetes, hypertension, kidney disease, mental illness, and tuberculosis. This should include checking invoices issued after the relevant effective date and verifying that the proper VAT treatment was applied.

ASG Law Can Assist with BIR and VAT Compliance

RMC No. 17-2024 is a reminder that VAT compliance for healthcare and pharmaceutical businesses is not static. The list of VAT-exempt medicines can change through FDA-endorsed updates, and businesses must keep their accounting systems aligned with those changes. Ablola, Saribong & Gueco advises companies on BIR compliance, VAT classification, tax audit risk, invoicing requirements, and regulatory coordination for healthcare, pharmaceutical, and general business clients. For assistance with VAT-exempt medicines, BIR compliance reviews, and tax risk management, contact Ablola, Saribong & Gueco through MakatiLawFirm.com.


Leave a Comment

Your email address will not be published. Required fields are marked *